Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer’s disease correlates with pathology
详细信息 查看全文
- 作者：Andrea FN Rosenberger ; Annemieke JM Rozemuller…
- 关键词：Alzheimer’s disease ; EphA4 kinase ; Synapse ; Immunohistochemistry
- 刊名：Acta Neuropathologica Communications
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：2
- 期：1
- 全文大小：2,776 KB
- 参考文献：1. Selkoe, DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81: pp. 741-766
2. DeKosky, ST, Scheff, SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 27: pp. 457-464 CrossRef
3. Arendt, T (2009) Synaptic degeneration in Alzheimer’s disease. Acta Neuropathol 118: pp. 167-179 CrossRef
4. Terry, RD, Masliah, E, Salmon, DP, Butters, N, DeTeresa, R, Hill, R, Hansen, LA, Katzman, R (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: pp. 572-580 CrossRef
5. Chen, Y, Fu, AKY, Ip, NY (2012) Eph receptors at synapses: Implications in neurodegenerative diseases. Cell Signal 24: pp. 606-611 CrossRef
6. Chen, Y, Fu, AKY, Ip, NY (2008) Bidirectional signaling of ErbB and Eph receptors at synapses. Neuron Glia Biol 4: pp. 211-221 CrossRef
7. Pasquale, EB (2008) Eph-Ephrin Bidirectional Signaling in Physiology and Disease. Cell 133: pp. 38-52 CrossRef
8. Castellani, V, Yue, Y, Gao, PP, Zhou, R, Bolz, J (1998) Dual action of a ligand for Eph receptor tyrosine kinases on specific populations of axons during the development of cortical circuits. J Neurosci 18: pp. 4663-4672
9. Dottori, M, Hartley, L, Galea, M, Paxinos, G, Polizzotto, M, Kilpatrick, T, Bartlett, PF, Murphy, M, K?ntgen, F, Boyd, AW (1998) EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract. Proc Natl Acad Sci U S A 95: pp. 13248-13253 CrossRef
10. Flanagan, JG, Vanderhaeghen, P (1998) The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21: pp. 309-345 CrossRef
11. Coulthard, MG, Morgan, M, Woodruff, TM, Arumugam, TV, Taylor, SM, Carpenter, TC, Lackmann, M, Boyd, AW (2012) Eph/ephrin signaling in injury and inflammation. Am J Pathol 181: pp. 1493-1503 CrossRef
12. Hollingworth, P, Harold, D, Sims, R, Gerrish, A, Lambert, JC, Carrasquillo, MM, Abraham, R, Hamshere, ML, Pahwa, JS, Moskvina, V, Dowzell, K, Jones, N, Stretton, A, Thomas, C, Richards, A, Ivanov, D, Widdowson, C, Chapman, J, Lovestone, S, Powell, J, Proitsi, P, Lupton, MK, Brayne, C, Rubinsztein, DC, Gill, M, Lawlor, B, Lynch, A, Brown, KS, Passmore, PA, Craig, D (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43: pp. 429-435 CrossRef
13. Tournoij, E, Koekman, CA, Du, VX, Roest, M, Ruijtenbeek, R, Moll, FL, Akkerman, JW (2012) Receptor contributes to granule secretion through Ephrin A4 receptor. Platelets 23: pp. 1-10 CrossRef
14. Bowden, TA, Aricescu, AR, Nettleship, JE, Siebold, C, Rahman-Huq, N, Owens, RJ, Stuart, DI, Jones, EY (2009) Structural Plasticity of Eph Receptor A4 Facilitates Cross-Class Ephrin Signaling. Structure 17: pp. 1386-1397 CrossRef
15. Tremblay, M-E, Riad, M, Bouvier, D, Murai, KK, Pasquale, EB, Descarries, L, Doucet, G (2007) Localization of EphA4 in axon terminals and dendritic spines of adult rat hippocampus. J Comp Neurol 501: pp. 691-702 CrossRef
16. Bouvier, D, Corera, AT, Tremblay, M-E, Riad, M, Chagnon, M, Murai, KK, Pasquale, EB, Fon, EA, Doucet, G (2008) Pre-synaptic and post-synaptic localization of EphA4 and EphB2 in adult mouse forebrain. J Neurochem 106: pp. 682-695
文摘
Synaptic dysfunction occurs early in the progression of Alzheimer’s disease (AD) and correlates with memory decline. There is emerging evidence that deregulation of Erythropoietin-producing hepatocellular (Eph) receptor tyrosine kinases (RTK) signaling contributes to the aberrant synaptic functions associated with neurodegeneration. The Eph receptor A4 is highly expressed in human adult hippocampal brain tissue and was previously linked to cognitive impairment in a transgenic mouse model for AD. Whether EphA4 levels are altered in AD brain remains elusive. Therefore we investigated the protein levels and localization of EphA4 in human hippocampus derived from AD (n--9) as well as non-demented control cases (n--9). The total EphA4 protein levels were not changed in AD patients compared to control cases. However, immunohistochemical localization of EphA4 revealed an altered distribution in AD compared to control hippocampus. EphA4 immunoreactivity was observed in plaque-like structures in AD cases. Double-labelling with phosphorylated tau and amyloid beta indicates that EphA4 co-localizes with neuritic plaques in AD. This altered distribution pattern was observed at early stages (Braak stage II) and correlates with the hallmarks of AD pathology suggesting a reduced availability of EphA4 that is likely to contribute to synaptic dysfunction that occurs early in AD.